
Johnson & Johnson Highlights New Data, Demonstrating Long-Term Sustained Disease Control In Adults Living With ...
Up to 128 weeks and 180 patient years of follow-up in the open label extension phase demonstrates a safety profile consistent with the Phase 3 Vivacity-MG3 study45% of the patients receiving steroids at open label extension baseline were able to decrease …